Quarterly report pursuant to Section 13 or 15(d)

Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details)

v3.22.1
Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Additions $ (250)
2020 Convertible Note [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Beginning Balance  
Additions   3,746
Measurement adjustments   4
Settlement   (3,750)
Ending Balance  
Warrants [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Beginning Balance  
Additions   635
Measurement adjustments   (214)
Settlement   (421)
Ending Balance  
Embedded Derivative [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Beginning Balance   1,690
Additions   325
Measurement adjustments   250
Settlement   (2,265)
Ending Balance  
vivoPharm Business [Member]    
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]    
Beginning Balance 11,000  
Additions  
Measurement adjustments (4,500)  
Settlement  
Ending Balance $ 6,500